Robert Myles Elfont
Plus aucun poste en cours
Profil
Robert Myles Elfont worked as the Chief Medical Officer at Aimmune Therapeutics, Inc. before pursuing his education.
He received an undergraduate degree from the University of Pennsylvania and graduate and doctorate degrees from the University of Rochester Medical Center.
Anciens postes connus de Robert Myles Elfont
| Sociétés | Poste | Fin |
|---|---|---|
| AIMMUNE THERAPEUTICS, INC. | Directeur Technique/Scientifique/R&D | - |
Formation de Robert Myles Elfont
| University of Pennsylvania | Undergraduate Degree |
| University of Rochester Medical Center | Doctorate Degree |
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Sociétés liées
| Entreprise privées | 1 |
|---|---|
Aimmune Therapeutics, Inc.
 Aimmune Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Aimmune Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the research and development of desensitization treatments for peanut and other food allergies. Its portfolio includes the characterized oral desensitization immunotherapy system. The firm product include Palforzia, which is an oral immunotherapy indicated for the mitigation of allergic reactions, including anaphylaxis that may occur with accidental exposure to peanut. The company was founded on June 24, 2011 and is headquartered in Brisbane, CA. | Health Technology |
